Sharemaestro Newsreel

Earnings call transcript: Cumberland Pharmaceuticals swings on Q2 2026 reset

Cumberland Pharmaceuticals announced a strategic shift in Q2 2026, selling its commercial brands to Apotex Health to transition into a biopharmaceutical development company. This transaction significantly strengthened its balance sheet with $100 million at closing and an estimated $108 million in total net proceeds, …

Takeda aims for dengue vaccine inclusion in India's shots program

Japanese drugmaker Takeda Pharmaceutical is seeking to integrate its newly approved dengue vaccine, Qdenga, into India's national immunization program. This move follows the vaccine's approval by India's Central Drugs Standard Control Organisation last month. The initiative aims to combat dengue fever, which infected 120,000 …

Is Pacira BioSciences Inc (PCRX) Undervalued After Q2 Earnings B

Weekly Recap: Hims & Hers data-sharing suit and FDA panel backs peptides

Hims & Hers (HIMS) is facing lawsuits from the FTC, Los Angeles County, and Utah over alleged data-sharing with Meta and Snap, as well as deceptive billing practices. Simultaneously, the company is exploring opportunities in the peptides market after an FDA advisory panel recommended …

Cumberland outlines over 5 years of runway following $1.50 per share special dividend

Earnings Call Insights: Cumberland Pharmaceuticals (CPIX) Q2 2026 MANAGEMENT VIEW * “In June, our shareholders overwhelmingly approved the strategic transaction with Apotex Health, on July 1st, we successfully closed the agreement to integrate our branded U.S. commercial businesses.” (Founder, Chairman, President & CEO A. …

NYSE: HIMS Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm

Kessler Topaz Meltzer & Check, LLP is investigating potential federal securities law violations by Hims & Hers Health, Inc. (NYSE: HIMS) after the Federal Trade Commission filed a lawsuit accusing the company of sharing customers' medical information with third-party advertisers. Following this news, HIMS's …

Xeris Biopharma President, COO Kevin McCulloch sells 15,000 shares for $120,240

Xeris Biopharma President and COO Kevin McCulloch sold 15,000 common shares for $120,240 on August 3, 2026, at a price of $8.02 per share. Following this transaction, his direct stake increased to 1,676,126 shares. The report also noted his spouse indirectly holds 25,000 shares.

Cumberland Pharmaceuticals posts $4.1 million Q2 loss after Apotex deal

Cumberland Pharmaceuticals (CPIX) reported a net loss of $4.1 million and net revenues of $166,458 for the second quarter of 2026, leading to a $0.27 loss per share. This follows a strategic transaction where Apotex Health acquired Cumberland’s FDA-approved brand portfolio for $100 million …

Cumberland Pays $1.50 Dividend After Apotex Brand Sale

Cumberland Pharmaceuticals announced its Q2 2026 financial results and the completion of a $100 million strategic transaction with Apotex Health, involving the sale of its FDA-approved brands. Following this deal, Cumberland is transitioning to a development-stage biopharmaceutical company and has declared a special cash …

Pacira BioSciences Q2 revenue rises 6% to $192.4 million

Pacira BioSciences reported a 6% increase in Q2 2026 revenue, reaching $192.4 million, with GAAP net income of $4.7 million. The company completed the divestiture of its iovera° business and updated its full-year revenue guidance to $735 million to $760 million. Insider trading activity …

Kiniksa Pharmaceuticals (KNSA) director converts 403 RSUs to shares

Kiniksa Pharmaceuticals director Richard S. Levy received an award of 403 Restricted Share Units (RSUs) on August 1, 2026. These RSUs vested immediately upon grant and were subsequently converted into 403 Class A Ordinary Shares. Following this transaction, Levy's direct holdings in the company …

Organigram (TSX:OGI) Goes Deeper Into Germany With New Deal

Organigram (TSX:OGI), a Canadian cannabis producer, announced a significant acquisition in Germany. This move allows the company to gain established medical brands and distribution channels in Europe's rapidly expanding medical cannabis market. The acquisition is part of Organigram's strategy to use its domestic recreational …

Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Dr. Reddy's Laboratories has launched Sugammadex Injection 200 mg/2 mL and 500 mg/5 mL Single-Dose Vials in the U.S., a generic equivalent of Bridion®. This first-to-market launch expands their hospital portfolio and aims to provide affordable, high-quality medicine. The product is indicated for reversing …

PHIBRO ANIMAL HEALTH CORP SEC Filing (Aug 4, 2026)

This article details a Form 144 SEC filing by Phibro Animal Health Corp (PAHC) on August 4, 2026. The filing indicates a proposed sale of 486 shares of Class A common stock by an individual, acquired through restricted stock vesting. The aggregate market value …

Pacira BioSciences Reports Second Quarter 2026 Financial Results

Pacira BioSciences reported solid financial results for the second quarter of 2026, with total revenue reaching $192.4 million, a 6% year-over-year increase. The company highlighted progress on its 5x30 strategy, including the divestiture of its iovera® business, expanded reimbursement for EXPAREL® by UnitedHealthcare, and …

Earnings Flash (PCRX) Pacira BioSciences, Inc. Posts Q2 Adjusted EPS $0.73 per Share, vs. FactSet Est of $0.65

Pacira BioSciences, Inc. (PCRX) announced its Q2 adjusted EPS was $0.73 per share, surpassing the FactSet estimate of $0.65. The company also reported Q2 revenue of $192.4 million, exceeding the FactSet estimate of $191.1 million, and provided updated earnings guidance for the full year …

Insider Buying: Tilray Brands (NASDAQ:TLRY) CFO Purchases $46,200.00 in Stock

Tilray Brands CFO Carl Merton recently purchased 10,000 shares of the company's stock for $46,200, increasing his direct holdings by over 7%. This transaction comes as Tilray's shares rose slightly, despite the company reporting a quarterly loss that missed analyst estimates, though revenue exceeded …

United Therapeutics earnings on deck after first-quarter miss By Investing.com

United Therapeutics is scheduled to report its second-quarter earnings, with analysts anticipating an improvement from a disappointing first quarter. Investors will be closely watching the performance of its pulmonary arterial hypertension (PAH) franchise and updates on the company's diversification strategy. Despite recent stumbles, Wall …

BioCryst earnings on deck: Can Orladeyo sustain momentum?

BioCryst Pharmaceuticals is set to release its second-quarter earnings, with investors focused on the revenue performance of its flagship hereditary angioedema therapy, Orladeyo. Analysts anticipate strong sequential revenue growth, and the company is undergoing a strategic transformation involving cost reductions and the integration of …

Tilray Brands (TLRY) CFO purchases 10,000 shares, stake rises to 139,753

Tilray Brands, Inc. CFO Carl A. Merton purchased 10,000 shares of common stock at $4.62 per share on August 4, 2026, increasing his direct holdings to 139,753 shares. This transaction was an open market or private purchase and was not reported under a Rule …

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

Indivior Pharmaceuticals INDV has announced a definitive agreement to merge with Supernus Pharmaceuticals SUPN in a tax-free, all-stock merger of equals. The transaction will create a leading central nervous system (CNS)-focused biopharmaceutical company with a diversified portfolio of 11 marketed medicines spanning psychiatry, neurology …

Evolus Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against Evolus, Inc. (NASDAQ: EOLS) and reminds investors of the December 15, 2020 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Evolus made false and misleading …

Indivior Pharmaceuticals, Inc. Quarterly Earnings Report

Indivior Pharmaceuticals, Inc. (INDV) has released its Q2 2026 earnings report, detailing an increase in net revenue driven by strong U.S. sales of SUBLOCADE. The company also announced a proposed all-stock merger with Supernus Pharmaceuticals, Inc., which includes a conditional $1 billion special cash …

Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Analyst Consensus Points to 36% Upside Potential

Indivior Pharmaceuticals, Inc. (INDV) is positioned as a key player in opioid dependence treatment, with strong analyst consensus pointing to a 36% upside potential. The company's focus on buprenorphine-based treatments, robust revenue growth of 19.20%, and a product pipeline including SUBLOCADE and SUBOXONE contribute …

Evotec publishes company presentation outlining drug discovery strategy and outlook

Evotec has released a company presentation detailing its drug discovery strategy, which focuses on market-beating growth, targeting higher-value segments, and improving operational efficiency. Key elements include a cost-reduction plan aiming for over EUR 60 million in impact by FY 2025, including workforce reductions, and …

Journey Medical (DERM) Expected to Post Earnings on Tuesday

Journey Medical (NASDAQ:DERM) is anticipated to report its Q2 2026 earnings after the market closes on Tuesday, August 11th. Analysts predict a loss of $0.01 per share and revenue of $18.3590 million. The company's previous quarter missed EPS estimates but exceeded revenue expectations.

AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) and certain officers. The lawsuit alleges that Aquestive Therapeutics made materially false and misleading statements regarding the approval timeline for its drug Anaphylm, specifically related to human factors …

BofA reiterates Evotec stock Underperform rating on execution concerns

BofA Securities has reiterated an Underperform rating on Evotec (NASDAQ:EVO) with a $3.00 price target, following the company's fiscal 2025 results. Despite revenue and adjusted EBITDA largely meeting expectations, profitability challenges persist, as indicated by a low gross profit margin and projected unprofitability for …

$1.8bn merger unites Supernus and Indivior in CNS therapeutics play

Supernus Pharmaceuticals and Indivior Pharmaceutical are merging in an all-stock transaction valued at $1.8 billion, aiming to create a stronger entity in the CNS therapeutics space. The combined company, to be named Supernus, Inc., will leverage commercial and pipeline synergies across neurological and psychiatric …

Aquestive Therapeutics (AQST) Expected to Announce Earnings on Tuesday

Royal Bank of Canada Has $30.67 Million Stock Holdings in Haleon PLC Sponsored ADR $HLN

Royal Bank of Canada increased its holdings in Haleon PLC Sponsored ADR (HLN) by 8.5% in the first quarter, now owning 3.06 million shares valued at approximately $30.67 million. Institutional investors hold 6.67% of HLN, and the stock opened at $9.80 with a market …

Viatris Gears Up to Report Q2 Earnings: What's in the Cards?

Viatris (VTRS) is set to announce its second-quarter 2026 earnings on August 6th, with analysts expecting revenues of $3.68 billion and earnings per share of 62 cents. The company's performance will be influenced by factors such as geographical segment sales (Developed Markets, Emerging Markets, …

Sei Investments Co. Increases Stock Position in Dr. Reddy's Laboratories Ltd $RDY

Sei Investments Co. significantly increased its stake in Dr. Reddy's Laboratories Ltd by 79.3% in the first quarter, now owning 436,731 shares valued at $6.05 million. Despite this, analyst sentiment for Dr. Reddy's remains negative, with several downgrades to "Sell" ratings and the company …

Tilray Brands (TLRY) strategy chief buys 2,500 shares in open-market trade

Tilray Brands' Chief Strategy Officer, Denise M. Faltischek, purchased 2,500 shares of common stock at $4.78 per share on August 3, 2026, in an open-market transaction. This purchase increased her direct beneficial ownership to 141,285 shares, excluding unvested restricted stock units, and was not …

Is Phibro Animal Health (PAHC) Undervalued On Its Dividend Update?

Organigram Global (NASDAQ: OGI) sets Q3 2026 earnings call for Aug. 11